AR080321A1 - A COMPOSITION OF PROLONGED PHARMACEUTICAL RELEASE OF ENTACAPONA OR ITS SALTS, PREPARATION PROCESS AND METHOD OF TREATMENT OF PARKINSON'S DISEASE - Google Patents

A COMPOSITION OF PROLONGED PHARMACEUTICAL RELEASE OF ENTACAPONA OR ITS SALTS, PREPARATION PROCESS AND METHOD OF TREATMENT OF PARKINSON'S DISEASE

Info

Publication number
AR080321A1
AR080321A1 ARP110100595A AR080321A1 AR 080321 A1 AR080321 A1 AR 080321A1 AR P110100595 A ARP110100595 A AR P110100595A AR 080321 A1 AR080321 A1 AR 080321A1
Authority
AR
Argentina
Prior art keywords
salts
entacapona
parkinson
disease
composition
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Munish Talwar
Ritesh Kapoor
Girish Kumar Jain
Manoj Mashalkar
Sanjay Mate
Mandar Kodgule
Original Assignee
Wockhardt Research Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Research Center filed Critical Wockhardt Research Center
Priority to ARP110100595 priority Critical patent/AR080321A1/en
Publication of AR080321A1 publication Critical patent/AR080321A1/en

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicacion 1: Una composicion farmacéutica que comprende de 200 a 1000 mg de entacapona o sus sales, opcionalmente con otros excipientes farmacéuticamente aceptables. Reivindicacion 12: Una composicion farmacéutica que comprende alrededor de 30 mg a 300 mg de levodopa, 10 mg a 100 mg de carbidopa y 200 mg a cerca de 1000 mg de entacapona o sus sales, opcionalmente con otros excipientes farmacéuticamente aceptables.Claim 1: A pharmaceutical composition comprising 200 to 1000 mg of entacapone or its salts, optionally with other pharmaceutically acceptable excipients. Claim 12: A pharmaceutical composition comprising about 30 mg to 300 mg of levodopa, 10 mg to 100 mg of carbidopa and 200 mg to about 1000 mg of entacapone or its salts, optionally with other pharmaceutically acceptable excipients.

ARP110100595 2011-02-25 2011-02-25 A COMPOSITION OF PROLONGED PHARMACEUTICAL RELEASE OF ENTACAPONA OR ITS SALTS, PREPARATION PROCESS AND METHOD OF TREATMENT OF PARKINSON'S DISEASE AR080321A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ARP110100595 AR080321A1 (en) 2011-02-25 2011-02-25 A COMPOSITION OF PROLONGED PHARMACEUTICAL RELEASE OF ENTACAPONA OR ITS SALTS, PREPARATION PROCESS AND METHOD OF TREATMENT OF PARKINSON'S DISEASE

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP110100595 AR080321A1 (en) 2011-02-25 2011-02-25 A COMPOSITION OF PROLONGED PHARMACEUTICAL RELEASE OF ENTACAPONA OR ITS SALTS, PREPARATION PROCESS AND METHOD OF TREATMENT OF PARKINSON'S DISEASE

Publications (1)

Publication Number Publication Date
AR080321A1 true AR080321A1 (en) 2012-03-28

Family

ID=46003371

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110100595 AR080321A1 (en) 2011-02-25 2011-02-25 A COMPOSITION OF PROLONGED PHARMACEUTICAL RELEASE OF ENTACAPONA OR ITS SALTS, PREPARATION PROCESS AND METHOD OF TREATMENT OF PARKINSON'S DISEASE

Country Status (1)

Country Link
AR (1) AR080321A1 (en)

Similar Documents

Publication Publication Date Title
CY1122628T1 (en) USE OF ECHO-PENTAENOIC ACID ETHYL ESTER FOR THE TREATMENT OF HYPERTRIGLYCERIDEMIA
ECSP13012668A (en) 1-BENCILCICLOALQUILCARBOXÍLICOS ACIDS SUBSTITUTED AND ITS USE
PH12018501072A1 (en) Modified release orally administered amino acid formulations
ECSP11011235A (en) DICIANOPIRIDINS ALQUILAMINO-REPLACED AND ITS AMINO ACID ESTER PROPHARMS
EA201001577A1 (en) DPP-4 INHIBITOR IN A COMBINATION WITH AN ADDITIONAL ANTI-DIABETIC AGENT, TABLETS INCLUDING THE SPECIFIED COMPOSITIONS, THEIR APPLICATION AND METHOD OF THEIR PRODUCTION
CL2013000063A1 (en) A method of treating a subject comprising administering optionally deuterated n-ethyl-n-phenyl1,2-dihydroxy-4-hodroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, for the treatment of a disease autoimmune; a mixture thereof; Pharmaceutical composition and its preparation process.
EA033067B1 (en) Method for treating metabolic disorders in a patient having a contraindication for a biguanide compound
UA113962C2 (en) PHARMACEUTICAL COMPOSITION CONTAINING APOMORPHINE AS AN ACTIVE INGREDIENT
CR20150266A (en) MODIFIED RELEASE FORMULATIONS FOR OPROZOMIB
WO2012100043A3 (en) Controlled release oral pharmaceutical dosage forms comprising mgbg
PH12017501304A1 (en) Levodopa and carbidopa intestinal gel and method of use
CL2011001829A1 (en) 3'-n-desmethyl-4 '' - o- (2-diethylaminoetanoyl) -6-o-methyl-9a-aza-9a-homoerythromycin a, its salts and crystalline forms 1, 2 and 3; Preparation process; use to treat inflammatory diseases; pharmaceutical composition; and composition which also comprises another active compound.
NZ591328A (en) Single unit oral dose pharmaceutical composition comprising levodopa, carbidopa and entacapone or salts thereof
ECSP16005208A (en) STABLE ANTI-TUBERCULOSIS PHARMACEUTICAL COMPOSITION IN A FORM OF A COATED TABLET INCLUDING ISONIAZID GRANULES AND RIFAPENTINE GRANULES AND THEIR PREPARATION PROCESS
WO2014006571A3 (en) Extended-release pharmaceutical dosage forms of carbidopa and levodopa and processes of preparation thereof
AR080321A1 (en) A COMPOSITION OF PROLONGED PHARMACEUTICAL RELEASE OF ENTACAPONA OR ITS SALTS, PREPARATION PROCESS AND METHOD OF TREATMENT OF PARKINSON'S DISEASE
DOP2012000280A (en) COMBINATION OF AN NSAID AND AN AMINO ACID
AR080322A1 (en) AN ORAL DOSE PHARMACEUTICAL COMPOSITION UNIT THAT INCLUDES LEVODOPA, CARBIDOPA AND ENTACAPONE OR ITS SALTS. PREPARATION PROCESS. TREATMENT METHOD
BR112015028581A2 (en) low dosage pharmaceutical composition, acid utilization, method for treatment of inflammatory disease and pharmaceutical composition
IN2014MU01184A (en)
AR103448A1 (en) INTESTINAL GEL OF LEVODOPA AND CARBIDOPA AND METHODS OF USE
IN2014MU01185A (en)
UA102426C2 (en) Pharmaceutical composition with anti-inflammatory, cardio- and chondroprotective activity and action against nsaid induced gastropathy
CL2013003070A1 (en) 3-carboxy-n-ethyl-n, n-dimethylpropan-1-ammonium salts (2e) -3-carboxy acrylate, phosphatodihydrogen and 2,6-diohydyl-1,2,3,6-tetrahydropyrimidine-4-carboxylate; preparation procedure; and use in the treatment of cardiovascular diseases.
CY1114276T1 (en) USE OF PHYSOEXPENTOENOEIC ACID FOR HYPERTENGLERIC TREATMENT

Legal Events

Date Code Title Description
FB Suspension of granting procedure